




PHARMACEUTICAL 2017

PROVECTUS BIOPHARMACEUTICALS INC. Rank 276 of 292





PHARMACEUTICAL 2017

PROVECTUS BIOPHARMACEUTICALS INC. Rank 276 of 292

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 244% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Other Net Income, reducing the Economic Capital Ratio by 613% points.

The company's Economic Capital Ratio, given in the ranking table, is -476%, being 479% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	1,826
Cost of Goods Sold	0
Intangible Assets	2,241
Liabilities, Current	2,142
Liabilities, Non-Current	0
Other Assets	1,471
Other Compr. Net Income	0
Other Expenses	436
Other Liabilities	0
Other Net Income	-23,991
Other Revenues	0
Property and Equipment	72
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	5,611
Liabilities	2,142
Expenses	436
Revenues	0
Stockholders Equity	3,469
Net Income	-24,427
Comprehensive Net Income	-24,427
Economic Capital Ratio	-476%